B18.0 Chronic viral hepatitis B with delta-agent

Name of the Condition

• Chronic viral hepatitis B with delta-agent

Summary

Chronic viral hepatitis B with delta-agent is a persistent liver inflammation caused by concurrent infection with the hepatitis B virus (HBV) and the hepatitis D virus (HDV, or delta agent). This dual infection can accelerate liver damage, increasing the risk of fibrosis, cirrhosis, or hepatocellular carcinoma compared to HBV infection alone. The condition often progresses silently in early stages but may present with nonspecific symptoms as liver function declines.

Causes

Chronic viral hepatitis B with delta-agent occurs when an individual with chronic HBV infection is superinfected with HDV. HDV requires the presence of HBV to replicate, as it uses HBV surface antigens for its own viral envelope. Transmission routes for HDV mirror those of HBV, including blood-to-blood contact, unprotected sexual contact, or perinatal exposure. Co-infection with both viruses is necessary for the delta agent to establish a chronic infection.

Risk Factors

• Chronic HBV infection, as HDV requires HBV for replication.
• Exposure to infected blood or bodily fluids, such as through sharing needles or unscreened blood products.
• Unprotected sexual contact with an HDV-positive individual.
• Perinatal transmission from an infected mother to her child.
• Immunocompromised states, which may worsen disease progression.

Symptoms

• Fatigue, malaise, or unexplained weight loss.
• Abdominal discomfort, particularly in the right upper quadrant.
• Jaundice (yellowing of the skin or eyes).
• Dark urine or pale stools.
• Easy bruising or bleeding due to impaired liver function.
• Hepatomegaly (enlarged liver) in advanced cases.

Diagnosis

Diagnosis involves serologic testing to detect both HBV and HDV markers. Key tests include HBsAg (hepatitis B surface antigen) to confirm chronic HBV, anti-HDV antibodies to identify delta agent exposure, and HDV RNA to confirm active replication. Liver function tests (ALT, AST) and imaging (e.g., ultrasound) assess liver damage. A liver biopsy may be performed to evaluate fibrosis or cirrhosis in advanced cases.

Treatment Options

Treatment focuses on suppressing viral replication and managing liver damage. Antiviral therapies for HBV (e.g., tenofovir, entecavir) are used, though HDV-specific treatments are limited. Pegylated interferon-alpha may be considered for select patients. Regular monitoring of liver function and viral loads is essential. In advanced cases, liver transplantation may be necessary.

Prognosis and Follow-Up

Prognosis depends on disease stage at diagnosis and response to treatment. Co-infection with HDV often leads to faster progression to cirrhosis or liver failure compared to HBV alone. Regular follow-up with liver function tests, viral load monitoring, and imaging is critical. Patients should avoid alcohol and hepatotoxic medications to reduce further liver injury.

Complications

• Progressive liver fibrosis and cirrhosis.
• Hepatocellular carcinoma (HCC), with increased risk due to dual infection.
• Liver failure, requiring transplantation in severe cases.
• Increased risk of hepatotoxicity from other medications or alcohol.

Lifestyle & Prevention

• Vaccination against HBV (does not protect against HDV but prevents HBV-related complications).
• Avoid sharing needles or personal items that may contact blood.
• Practice safe sex to reduce transmission risk.
• Limit alcohol consumption and avoid hepatotoxic substances.
• Regular screening for high-risk individuals (e.g., those with chronic HBV).

When to Seek Professional Help

Seek medical attention if you experience jaundice, severe abdominal pain, unexplained weight loss, or signs of liver failure (e.g., confusion, bleeding). Prompt evaluation is critical for early intervention and to prevent complications.

Tips for Medical Coders

Document the presence of chronic HBV and delta-agent co-infection to support the B18.0 code. Include details on serologic test results (e.g., HBsAg positivity, anti-HDV antibodies) and clinical findings (e.g., liver function abnormalities) to confirm the diagnosis. Ensure documentation aligns with the dual viral etiology, as this distinguishes it from other chronic hepatitis B codes.